These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24935478)

  • 1. Stratification and partial ascertainment of biomarker value in biomarker-driven clinical trials.
    Simon R
    J Biopharm Stat; 2014; 24(5):1011-21. PubMed ID: 24935478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial.
    Ji L; McShane LM; Krailo M; Sposto R
    Clin Trials; 2019 Dec; 16(6):599-609. PubMed ID: 31581815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.
    Barry WT; Perou CM; Marcom PK; Carey LA; Ibrahim JG
    J Biopharm Stat; 2015; 25(1):66-88. PubMed ID: 24836519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient testing of the biomarker positive and negative subgroups in a biomarker-stratified trial.
    Li L; Ivanova A
    Biometrics; 2024 Mar; 80(2):. PubMed ID: 38861372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Run-in phase III trial design with pharmacodynamics predictive biomarkers.
    Hong F; Simon R
    J Natl Cancer Inst; 2013 Nov; 105(21):1628-33. PubMed ID: 24096624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive biomarker validation in practice: lessons from real trials.
    Mandrekar SJ; Sargent DJ
    Clin Trials; 2010 Oct; 7(5):567-73. PubMed ID: 20392785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Power estimation in biomarker studies where events are already observed.
    Polley MC
    Clin Trials; 2017 Dec; 14(6):621-628. PubMed ID: 28776405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designing a study to evaluate the benefit of a biomarker for selecting patient treatment.
    Janes H; Brown MD; Pepe MS
    Stat Med; 2015 Nov; 34(27):3503-15. PubMed ID: 26112650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the causal effect of randomization versus treatment preference in a doubly randomized preference trial.
    Marcus SM; Stuart EA; Wang P; Shadish WR; Steiner PM
    Psychol Methods; 2012 Jun; 17(2):244-54. PubMed ID: 22563844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficiency of clinical trial designs for predictive biomarker validation.
    Young KY; Laird A; Zhou XH
    Clin Trials; 2010 Oct; 7(5):557-66. PubMed ID: 20571132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of phase II trial designs for initial marker validation.
    Mandrekar SJ; An MW; Sargent DJ
    Contemp Clin Trials; 2013 Nov; 36(2):597-604. PubMed ID: 23665336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Controlled Trials 5: Biomarkers and Surrogates/Outcomes.
    Rigatto C; Barrett BJ
    Methods Mol Biol; 2021; 2249():261-280. PubMed ID: 33871849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development program.
    Wang SJ
    J Formos Med Assoc; 2008 Dec; 107(12 Suppl):19-27. PubMed ID: 19129042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers.
    Sargent DJ; Mandrekar SJ
    Clin Trials; 2013 Oct; 10(5):647-52. PubMed ID: 23983158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of treatment effects in all-comers randomized clinical trials with a predictive marker.
    Choai Y; Matsui S
    Biometrics; 2015 Mar; 71(1):25-32. PubMed ID: 25303178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of archived specimens in evaluation of prognostic and predictive biomarkers.
    Simon RM; Paik S; Hayes DF
    J Natl Cancer Inst; 2009 Nov; 101(21):1446-52. PubMed ID: 19815849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial designs for testing biomarker-based personalized therapies.
    Lai TL; Lavori PW; Shih MC; Sikic BI
    Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On study designs and hypotheses for clinical trials with predictive biomarkers.
    Shih WJ; Lin Y
    Contemp Clin Trials; 2017 Nov; 62():140-145. PubMed ID: 28838813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarker detection and subgroup identification.
    Zhao Y; Zheng W; Zhuo DY; Lu Y; Ma X; Liu H; Zeng Z; Laird G
    J Biopharm Stat; 2018; 28(3):534-549. PubMed ID: 29020511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.